openFDA
Cure8 regulatory brief
Tofacitinib FDA label update (2026-07-23)
Medications
Tofacitinib
JAK inhibitor
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Ulcerative colitis
Why This Matters
An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of updated indications, boxed warnings, and limits on combining with other immunosuppressants.
Who Should Pay Attention
Adults with ulcerative colitis considering or taking tofacitinib; clinicians who prescribe IBD therapies; caregivers; patients with prior TNF blocker exposure.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA (DailyMed) drug label update for tofacitinib (a JAK inhibitor). The label includes indications across rheumatology and inflammatory bowel disease, specifically noting an indication for moderately to severely active ulcerative colitis in adults after inadequate response or intolerance to TNF blockers.
It also contains boxed warnings covering serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, plus limitations on combining tofacitinib with biologic therapies or potent immunosuppressants.
The label text is a regulatory record: it describes approved uses, contraindications/limitations, and safety warnings rather than new clinical trial results.
If you take tofacitinib or are considering it for UC, read this label with your prescribing clinician to understand risks, monitoring requirements (for example, testing for latent TB and watching for infections), and dosing cautions.
Keep In Mind
This is an official drug-label (regulatory) record on DailyMed summarizing approved uses and safety information. It reports label language and warnings rather than new clinical trial findings.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorAvKARE
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 23, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TOFACITINIB FDA label update (2026-07-06)
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
DailyMed label update for RINVOQ
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...